Systemic sclerosis

British Journal of Hospital Medicine

Volumn 73, Issue 9, 2012, Pages 509-516

  Hughes, Michael ^a   Herrick, Ariane ^b  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866677465     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2012.73.9.509     Document Type: Review

References (33)

1. Bhattacharyya S, Wei J, Varga J (2011) Understanding fibrosis in systemic sclerosis: Shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8(1): 42-54
2. Cutolo M, Sulli A, Smith V et al (2010) Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 6(10): 578-87
3. Denton CP, Lapadula G, Mouthon LU, Müller-Ladner U (2009) Renal complications and scleroderma renal crisis. Rheumatology 48(suppl 3): Iii32-iii35
4. Forbes A, Marie I (2008) Gastrointestinal complications: The most frequent internal complications of systemic sclerosis. Rheumatology 48(suppl 3): Iii36-iii39
5. Fransen J, Johnson SR, Van Den Hoogen F et al (2012) Items for developing revised classification criteria in systemic sclerosis: Results of a consensus Exercise. Arthritis Care Res 64(3): 351-7
6. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19): 1989-2003
7. Goundry B, Langtree M, Moorthy A (2012) Diagnosis and management of Raynaud's phenomenon. BMJ 344: E289
8. Gyger G, Baron M (2012) Gastrointestinal manifestations of scleroderma: Recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 14(1): 22-9
9. Haustein UF (2005) Scleroderma and pseudoscleroderma: Uncommon presentations. Clin Dermatol 23(5): 480-90
10. Herrick AL (2011) Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr Opin Rheumatol 23(6): 555-61
11. Hoyles RK, Ellis RW, Wellsbury J et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12): 3962-70
12. Hummers LK, Hall A, Wigley FM, Simons M (2009) Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 36(3): 576-82
13. Kahan A, Coghlan G, McLaughlin V (2009) Cardiac complications of systemic sclerosis. Rheumatology 48(suppl 3): Iii45-iii48
14. Kallenberg CG (1990) Early detection of connective tissue disease in patients with Raynaud's phenomenon. Rheum Dis Clin North Am 16(1): 11-30
15. Katsumoto TR, Whitfield ML, Connolly MK (2011) The pathogenesis of systemic sclerosis. Annu Rev Pathol 6: 509-37
16. Koenig M, Joyal F, Fritzler MJ et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58(12): 3902-12
17. Kowal-Bielecka O, Landewé R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68(5): 620-8
18. Krieg T, Takehara K (2009) Skin disease: A cardinal feature of systemic sclerosis. Rheumatology 48(suppl 3): Iii14-iii18
19. Le Pavec, Humbert M, Mouthon L, Hassoun PM (2010) Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 181(12): 1285-93
20. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 15(2): 202-5
21. Masi AT, Rodnan GP, Medsger TA et al (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581-90
22. Nashel J, Steen V (2012) Scleroderma mimics. Curr Rheumatol Rep 14(1): 39-46
23. Nihtyanova SI, Denton CP (2007) Therapy of pulmonary arterial hypertension in systemic sclerosis: An update. Curr Rheumatol Rep 9(2): 158-64
24. Nihtyanova SI, Denton, CP (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6(2): 112-16
25. Nikpour M, Stevens WM, Herrick AL, Proudman SM (2010) Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol 24(6): 857-69
26. Quillinan NP, Denton CP (2009) Disease-modifying treatment in systemic sclerosis: Current status. Curr Opin Rheumatol 21(6): 636-41
27. Steen V, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66(7): 940-4
28. Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma. N Engl J Med 354(25): 2655-66
29. Tyndall AJ, Bannert, B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10): 1809-15
30. Valentini G, Black C (2002) Systemic Sclerosis. Best Pract Res Clin Rheumatol 16(5): 807-16
31. Wells AU, Steen V, Valentini G (2009) Pulmonary complications: One of the most challenging complications of systemic sclerosis. Rheumatology 48(suppl 3): Iii40-iii44
32. Wigley FM (2002) Raynaud's phenomenon. N Engl J Med 347: 1001-8
33. Williams MH, Das C, Handler CE et al (2006) Systemic sclerosis associated pulmonary hypertension: Improved survival in the current era. Heart 92: 926-32